Drugs / A140
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04835142 | Dec 2020 → Mar 2023 | colorectal cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A140 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04835142 ↗ |
| Action | Inhibit | “EGFR inhibition” PMID 40737898 ↗ Jun 2025 |
| Route | Intravenous | “Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv）” NCT04835142 ↗ |
| Target | EGFR | “EGFR inhibition” PMID 40737898 ↗ Jun 2025 |